Bacillus thuringiensis (Bt) proteins are developed for genetically modified crops and the Bt proteins demonstrate no evidence of toxicity by the oral route in traditional animal models.  However, the possible toxicity of Bt proteins under conditions of reduced gastric acid secretion and/or small intestinal damage has not been investigated.  In the present study, we therefore evaluated following four F344 rat groups with a purified Bt protein Cry1Ab from B. thuringiensis var. Kurustaki HD-1.  Gastrointestinal impairment (GI) alone and GI + Bt protein fed (GI + Bt) groups were given i.p. injections of famotidine to reduce gastric acid secretion twice a day at 30 mg/kg body weight in weeks 2 and 4.  GI and GI + Bt groups were additionally fed diets containing 80 ppm indomethacin for induction of intestinal damage during weeks 1 and 3.  Bt alone and GI + Bt groups were also fed diet containing Bt protein Cry1Ab at a concentration of 10 ppm in weeks 2 and 4.  A no treatment control group was also included.  At the end of week 4, all animals were euthanized under ether anesthesia, blood samples were collected for hematology and serum biochemistry and a complete necropsy was performed.  No significant changes indicative of toxicity of the Bt protein Cry1Ab used here were noted with any of the parameters investigated.  In conclusion, no significant toxicological effects were detected in this subchronic gastrointestinal impairment rat model.